Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome in Pediatric Lymphoma and Solid Tumors
NCT05620862Phase 1Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2022
- Primary completion
- Sep 2024
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in lymphoma and solid tumor, sponsored by Sun Yat-sen University. Primary endpoints: Maximum-tolerated dose at 21 days, Peak time at 18 weeks and 4 more. Started Oct 2022; status: active, not recruiting.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
lymphomasolid tumor
Beyond the preview
Go deeper on NCT05620862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620862.